Remdesivir has FDA approval for use in adults and pediatric patients 12 years of age and older and weighing at least 40 kg (about 88 pounds) requiring hospitalization and the use of supplemental oxygen. Preliminary report recommends using Dexamethasone in patients who are mechanically ventilated and in patients who require supplemental oxygen but who are not mechanically ventilated. Recommendations are against using Dexamethasone in patients who do not require supplemental oxygen. If Dexamethasone is not available, use alternative glucocorticoids such as Prednisone, Methylprednisolone, or Hydrocortisone. The FDA indicates there is no evidence linking the use of NSAIDs with the worsening of the disease; hence, persons taking NSAIDs for a co-morbid condition should continue therapy as previously directed by their physician. The use of prescribed statins for treatment or prevention of cardiovascular disease should continue; however, recommendations are against the use of statins for the treatment of COVID-19 outside of the setting of a clinical trial.
SNOMED_CT Problem=191415002 (PB0050); SNOMED_CT Cat-Tar=409022004 (CG0003, TG0073)